About the Company
We do not have any company description for HilleVax, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on HilleVax, Inc.
HilleVax, Inc. (NASDAQ:HLVX) is largely controlled by institutional ...
Every investor in HilleVax, Inc. (NASDAQ:HLVX) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 51% to be precise, is ...
HilleVax, Inc: Analyst Maintains Hold Rating Amid Vaccine Trial Setback ...
Matthew Caufield has given his Hold rating due to a combination of factors influencing HilleVax, Inc’s current situation. The recent failure of the Phase 2B NEST-IN1 trial for the HIL-214 ...
Hillevax Shares Gain on Acquisition Deal with XOMA Royalty
Shares of Hillevax Inc (NASDAQ:HLVX) climbed 2.9% after the company revealed it had entered into a definitive merger agreement with XOMA Royalty Corporation (NASDAQ:XOMA), marking the latest in a ...
What Makes HilleVax (HLVX) a New Buy Stock - Nasdaq
HilleVax, Inc. (HLVX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics
XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA ...
HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued ...
Summary HilleVax, Inc. top line results from the phase 2/3 NEST-IN1 study, using HIL-214 for the prevention of Norovirus-related gastroenteritis, expected mid-2024.
HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade
HilleVax, Inc. (HLVX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
HilleVax, Inc.: HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
BOSTON, Mass., and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ: HLVX) and XOMA Royalty Corporation ...
HilleVax Announces Closing of Public Offering of Common Stock and Full ...
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has ...
Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation.
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive merger agreement (the ...
HilleVax, Inc. (NASDAQ:HLVX) is largely controlled by institutional ...
Every investor in HilleVax, Inc. (NASDAQ:HLVX) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 51% to be precise, is ...
Similar Companies
Loading the latest forecasts...